Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Useful Home Espresso Machines - 2Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 3Motivational Travel Objections for History Buffs
- 4Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 5Moving Wedding Objections for Paramount Functions
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- Instructions to Pick the Best Album Rates for Your Investment funds
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Vote in favor of your Favored sort of footwear
- 6 U.S. States for Climbing
- Travels to Dream Objections in Europe
- ‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
